Wall Street analysts expect Motus GI Holdings Inc (NASDAQ:MOTS) to announce sales of $80,000.00 for the current quarter, according to Zacks. Two analysts have provided estimates for Motus GI’s earnings, with the highest sales estimate coming in at $100,000.00 and the lowest estimate coming in at $50,000.00. The company is expected to issue its next earnings report on Wednesday, November 13th.
According to Zacks, analysts expect that Motus GI will report full-year sales of $710,000.00 for the current financial year, with estimates ranging from $410,000.00 to $1.00 million. For the next financial year, analysts forecast that the company will post sales of $13.84 million, with estimates ranging from $11.07 million to $16.60 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that follow Motus GI.
Motus GI (NASDAQ:MOTS) last released its quarterly earnings data on Friday, August 9th. The company reported ($0.26) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.03.
Motus GI stock traded down $0.05 during trading hours on Tuesday, hitting $2.69. 96,053 shares of the company traded hands, compared to its average volume of 72,937. The company has a quick ratio of 3.89, a current ratio of 3.92 and a debt-to-equity ratio of 0.08. The firm’s 50-day simple moving average is $2.84 and its two-hundred day simple moving average is $3.61. Motus GI has a 1-year low of $2.34 and a 1-year high of $7.40.
In related news, Chairman David P. Hochman bought 10,000 shares of the stock in a transaction on Monday, July 1st. The shares were purchased at an average price of $3.00 per share, with a total value of $30,000.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Life Sciences Maste Perceptive bought 1,000,000 shares of the stock in a transaction on Thursday, June 27th. The shares were bought at an average cost of $3.00 per share, for a total transaction of $3,000,000.00. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 2,054,332 shares of company stock worth $6,162,996. 18.14% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in MOTS. Perceptive Advisors LLC grew its stake in shares of Motus GI by 31.1% in the 2nd quarter. Perceptive Advisors LLC now owns 4,210,542 shares of the company’s stock worth $12,757,000 after purchasing an additional 1,000,000 shares during the last quarter. Oracle Investment Management Inc. grew its stake in shares of Motus GI by 35.7% in the 2nd quarter. Oracle Investment Management Inc. now owns 3,766,666 shares of the company’s stock worth $11,413,000 after purchasing an additional 991,666 shares during the last quarter. Maven Securities LTD acquired a new position in shares of Motus GI in the 2nd quarter worth approximately $1,037,000. Granite Point Capital Management L.P. acquired a new position in shares of Motus GI in the 2nd quarter worth approximately $1,010,000. Finally, Vanguard Group Inc. acquired a new position in shares of Motus GI in the 2nd quarter worth approximately $789,000. 40.33% of the stock is currently owned by institutional investors.
About Motus GI
Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
Further Reading: What is Elliott Wave theory?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.